Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $1.99, $0.15 worse than the analyst estimate of $2.14. Revenue for the quarter came in at $309.3 million versus the consensus estimate of $308.92 million.

Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.75, versus the consensus of $9.77. Jazz Pharmaceuticals sees FY2015 revenue of $1.3-1.37 billion, versus the consensus of $1.36 billion.

"We are pleased with our strong top-line performance during the first quarter, driven by sales growth of our key products," said Bruce C. Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "For 2015, we will remain focused on execution of our key objectives, including advancing our development pipeline, completing the rolling NDA submission for defibrotide, preparing for the potential launch of defibrotide in the U.S. and continuing our efforts to further diversify our business through corporate development activities."

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Texas Instruments (TXN) jumps as on earnings, revenue beat in fiscal Q1
• KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c